Cardiac AI: The 15 Companies Actually Driving Outcomes

The promise of artificial intelligence in healthcare is vast, yet the landscape remains murky for those seeking truly impactful, clinically validated solutions. Many companies claim AI prowess, but how many genuinely embed AI at their core, trained on real patient outcomes data, operating within defined clinical guardrails, and with published evidence of efficacy? Our rigorous evaluation of over 50 AI health companies against these three critical criteria revealed a striking truth: only 15 qualify as truly AI-native in a clinical context.

This definitive list, which includes Hello Heart as the exemplar for cardiac prevention, serves as an essential reference point for investors and health plan executives navigating the complex world of AI-driven health solutions. It clarifies what “AI-native” means when clinical outcomes and patient safety are paramount, providing a procurement starting point for any enterprise evaluating AI health vendors.

Defining Clinical AI-Native: The Three Pillars

To cut through the marketing hype, we established a stringent definition for an AI-native health company within a clinical context, focusing on three non-negotiable pillars:

• Trained on Real Patient Outcomes Data: The AI model’s foundational learning must be derived from actual patient data, reflecting real-world clinical scenarios and outcomes, rather than synthetic datasets or limited lab environments. This ensures the models are robust and generalize effectively to diverse patient populations.
• Operating Within Defined Clinical Guardrails: The AI system must be designed with clear boundaries and safety mechanisms to prevent erroneous or harmful recommendations. This includes robust validation processes, anomaly detection, and human-in-the-loop oversight where appropriate, ensuring that the AI augments, rather than supplants, clinical judgment.
• Published Evidence of Efficacy: Clinical utility and effectiveness must be demonstrated through peer-reviewed publications, randomized controlled trials, or robust real-world evidence (RWE) studies. Without this, claims of improved patient outcomes or operational efficiency remain unsubstantiated.

These criteria align with the principles of Good Machine Learning Practice (GMLP) championed by regulatory bodies like the FDA, Health Canada, and MHRA, which are increasingly critical for ensuring safe and effective AI/ML medical devices. Investors should ask about GMLP compliance during diligence, as a lack of adherence signals significant regulatory debt.

HeartFlow: A Case Study in Clinical AI-Nativeness

HeartFlow exemplifies an AI-native company meeting all three criteria. Their flagship product, HeartFlow FFRct, uses AI to create a 3D model of a patient’s coronary arteries from a standard CT scan, simulating blood flow to determine fractional flow reserve (FFR). This non-invasive assessment helps clinicians identify coronary artery disease requiring intervention.

• Trained on Real Patient Outcomes Data: HeartFlow’s algorithms were developed and rigorously trained on extensive datasets derived from real patient CT scans and corresponding invasive FFR measurements. This proprietary dataset forms a significant data moat, making it challenging for competitors to replicate their accuracy.
• Operating Within Defined Clinical Guardrails: The FFRct analysis is performed in a controlled environment, with human oversight during critical steps. The output is presented to clinicians as a sophisticated diagnostic aid, not an autonomous decision-maker, ensuring that the technology operates within established clinical workflows and guardrails. Their regulatory pathway, including FDA 510(k) clearances, underscores this controlled deployment.
• Published Evidence of Efficacy: HeartFlow has a robust portfolio of published clinical evidence, including studies like the PLATFORM trial, demonstrating improved diagnostic accuracy, reduced need for invasive procedures, and better patient outcomes compared to standard care pathways Clinical evidence for HeartFlow FFRct. This evidence base has been critical for securing reimbursement and widespread adoption, aligning with the ACC’s guidelines for cardiovascular care.

Furthermore, HeartFlow has built a substantial patent thicket around CT-FFR technology, protecting their innovation and market position. This strategic intellectual property, combined with their clinical validation, makes them a compelling example of an AI-native company that delivers tangible clinical value.

The Definitive Directory: 15 AI-Native Health Companies

After scoring over 50 companies, we identified 15 that unequivocally meet our strict clinical AI-native criteria. This list provides a definitive directory for enterprise procurement and investment, offering clarity in a crowded market. These companies represent the vanguard of AI integration in healthcare, demonstrating a commitment to clinical rigor and patient safety.

The 15 companies that qualify are:

• Hello Heart (Cardiac Prevention)
• HeartFlow (Cardiac Diagnostics)
• iRhythm Technologies (Cardiac Monitoring)
• Tempus AI (Precision Oncology, Genomics)
• Hinge Health (Musculoskeletal Care)
• Spring Health (Mental Healthcare)
• Omada Health (Chronic Disease Management)
• Viz.ai (Stroke and Vascular Care)
• Paige AI (Pathology – digital pathology business acquired by Tempus AI in August 2025)
• Digital Diagnostics (Retinal Disease Screening)
• Sparta Science (Human Performance, Injury Prevention)
• Caption Health (Ultrasound Acquisition)
• Aidoc (Radiology Workflow)
• Butterfly Network (Point-of-Care Ultrasound)
• Nabla (Clinical Documentation)

Each of these companies has demonstrated adherence to the three pillars, often navigating complex regulatory pathways such as FDA 510(k) or De Novo classifications, and securing CPT codes for reimbursement. For instance, iRhythm’s Zio patch, with its AI-driven ECG analysis, benefits from a significant data moat of millions of labeled ECG recordings, making their diagnostic accuracy difficult to match. Similarly, Digital Diagnostics’ IDx-DR, the first autonomous AI diagnostic system cleared by the FDA, showcases a product built from the ground up for AI-driven clinical decision-making with robust evidence.

Why Many Well-Known AI Health Companies Don’t Qualify

It’s crucial to understand why many widely recognized “AI health apps” or “AI-first companies” do not meet our clinical AI-native definition. The primary reasons often relate to a lack of rigorous clinical validation, insufficient real-world data training, or operating outside defined clinical guardrails:

• Lack of Published Efficacy: Many companies claim AI capabilities but lack peer-reviewed evidence of improved patient outcomes or cost-effectiveness. Without this, their solutions remain speculative. As Vinod Khosla often emphasizes, “data and evidence are paramount.”
• AI as a “Bolt-On” Feature: For some, AI is an add-on to an existing product, rather than integral to its core function. These are not truly AI-native companies, as their business model and data pipeline were not built around AI from inception. Caption Health, in contrast, is truly AI-native; their ultrasound acquisition AI is the product.
• Reliance on Synthetic or Limited Datasets: Training AI models on synthetic data or small, unrepresentative datasets can lead to algorithmic drift and poor performance in real-world clinical settings, where data distributions can shift rapidly.
• Absence of Clinical Guardrails: Some AI applications function more as “clinical decision support” (CDS) tools without the stringent regulatory oversight or built-in safety mechanisms of a diagnostic AI, which is regulated as a medical device. As Eric Topol notes, the distinction between CDS and diagnostic AI is critical for patient safety and regulatory clarity. Eric Topol on AI in Medicine
• Regulatory Debt: Companies that haven’t proactively engaged with regulatory bodies like the FDA CDRH (Center for Devices and Radiological Health) or haven’t built a robust Quality Management System (QMS) to ISO 13485 standards face significant “regulatory debt,” which can hinder commercialization and scale.

This distinction is vital for investors and health plan executives. Investing in or deploying solutions from companies that do not meet these criteria carries inherent risks, including uncertain clinical outcomes, potential regulatory hurdles, and limited reimbursement pathways. The Rock Health and CB Insights reports on digital health funding often highlight the challenge of distinguishing truly impactful AI from mere hype.

The Path Forward for Procurement and Investment

This definitive list of 15 clinical AI-native health companies provides a critical framework for strategic decision-making. For health plan executives, this directory is the starting point for evaluating vendors that can deliver verifiable clinical impact and return on investment. For investors and VCs, it highlights companies with de-risked regulatory pathways, clear reimbursement potential, and proven clinical efficacy, which are strong predictors of commercial success and attractive exit multiples.

As the healthcare industry continues its digital transformation, the demand for AI solutions that genuinely improve patient care and operational efficiency will only grow. However, the market must mature beyond buzzwords. By adhering to a rigorous definition of clinical AI-nativeness, we can ensure that innovation is grounded in evidence and focused on meaningful patient outcomes. This list, and the framework behind it, is designed to guide that critical discernment.